动脉瘤性蛛网膜下腔出血患者早期脑损伤生物标志物的研究进展  

Research progress of biomarkers for early brain injury in patients with aneurysmal subarachnoid hemorrhage

作　　者：张杰 彭俊[2] Zhang Jie;Peng Jun(Department of Emergency,Haikou People′s Hospital,Haikou 570208,China)

机构地区：[1]海口市人民医院急诊科,570208 [2]海口市人民医院神经外科,570208

出　　处：《中国脑血管病杂志》2021年第12期876-880,共5页Chinese Journal of Cerebrovascular Diseases

基　　金：国家自然科学基金(81760234)。

摘　　要：动脉瘤性蛛网膜下腔出血(aSAH)是致死和致残的重大疾病之一,早期脑损伤(EBI)是aSAH预后不良的决定性因素。因此,寻找具有评估治疗效果及预后的EBI生物标志物,将aSAH患者分层,并客观监测EBI治疗的反应是必要的。该文对aSAH患者EBI的概念、机制及其相关生物标志物进行了综述,以期为诊断和治疗aSAH,开发aSAH靶标药物,进而改善aSAH患者的预后提供一定依据。Aneurysmal subarachnoid hemorrhage(aSAH)is an important cause of mortality and morbidity.Early brain injury(EBI)is the main determinant of poor prognosis of aSAH.Therefore,it is necessary to search EBI biomarkers with good prognostic and therapeutic significance for stratifying patients with aSAH and monitoring their response to EBI treatment objectively.The concept,mechanism and related biomarkers of EBI were reviewed in order to provide a theoretical basis for the diagnosis and treatment of aSAH as well as the development of target medications to finally improve the prognosis of aSAH patients.

关 键 词：动脉瘤性蛛网膜下腔出血 早期脑损伤 生物标志物 综述 

分 类 号：R743.35[医药卫生—神经病学与精神病学]